Logo-apb

Journal Info:

Freq.: Quarterly

eISSN: 2251-7308 
pISSN: 2228-5881 

Permission: CC By

Platinum Open Access

(no submission or publication fees)

Powered by
Adv Pharm Bull. 2020;10(2): 264-270. doi: 10.34172/apb.2020.031
PMID: 32373495        PMCID: PMC7191242

Research Article

Helicobacter pylori Recombinant CagA Regulates Th1/Th2 Balance in a BALB/c Murine Model

Nafiseh Paydarnia 1,2, Behzad Mansoori 1,3 ORCID, Davoud Esmaeili 4, Tohid Kazemi 1 ORCID, Mahyar Aghapour 5 ORCID, Khalil Hajiasgharzadeh 1, Nazila Alizadeh 1, Behzad Baradaran 1 * ORCID

Cited by CrossRef: 12

1- Ranjbariyan A, Haghighat S, Yazdi M, Arbabi Bidgoli S. Synthetic selenium nanoparticles as co-adjuvant improved immune responses against methicillin-resistant Staphylococcus aureus. World J Microbiol Biotechnol. 2023;39(1) [Crossref]
2- Nahian M, Khan M, Rahman F, Reza H, Bayil I, Nodee T, Basher T, Sany M, Munmun R, Habib S, Mazumder L, Acharjee M, Moin A. Immunoinformatic strategy for developing multi-epitope subunit vaccine against Helicobacter pylori. PLoS ONE. 2025;20(2):e0318750 [Crossref]
3- Portillo-Miño J, Bettin-Gonzalez D, Coral F. mRNA vaccines in gastric cancer: How close are we?. Vacunas. 2024;25(1):88 [Crossref]
4- Zhang Y, Li X, Shan B, Zhang H, Zhao L. Perspectives from recent advances of Helicobacter pylori vaccines research. Helicobacter. 2022;27(6) [Crossref]
5- Fan J, Zhu J, Xu H. Strategies of Helicobacter pylori in evading host innate and adaptive immunity: insights and prospects for therapeutic targeting. Front Cell Infect Microbiol. 2024;14 [Crossref]
6- Li S, Zhao W, Xia L, Kong L, Yang L. How Long Will It Take to Launch an Effective Helicobacter pylori Vaccine for Humans?. IDR. 2023;Volume 16:3787 [Crossref]
7- Ranjbariyan A, Haghighat S, Yazdi M, Bidgoli S, Tabriz H, Mahdavi M. Immunogenic potential of biogenic vs. synthetic selenium nanoparticles in vaccine candidate against methicillin-resistant Staphylococcus aureus. Vaccine: X. 2025;24:100650 [Crossref]
8- Elbehiry A, Marzouk E, Abalkhail A, Sindi W, Alzahrani Y, Alhifani S, Alshehri T, Anajirih N, ALMutairi T, Alsaedi A, Alzaben F, Alqrni A, Draz A, Almuzaini A, Aljarallah S, Almujaidel A, Abu-Okail A. Pivotal role of Helicobacter pylori virulence genes in pathogenicity and vaccine development. Front Med. 2025;11 [Crossref]
9- Emanuele E, Minoretti P. Letter: Disappearing Microbe, Emerging Disease? Nuancing the Protective Effects of Helicobacter pylori Against Eosinophilic Oesophagitis. Aliment Pharmacol Ther. 2025;61(9):1573 [Crossref]
10- Lu Y, Ning H, Kang J, Bai G, Zhou L, Kang Y, Wu Z, Tian M, Zhao J, Ma Y, Bai Y. Cyclic-di-AMP Phosphodiesterase Elicits Protective Immune Responses Against Mycobacterium tuberculosis H37Ra Infection in Mice. Front Cell Infect Microbiol. 2022;12 [Crossref]
11- Atrisco-Morales J, Ramírez M, Castañón-Sánchez C, Román-Román A, Román-Fernández I, Martínez-Carrillo D, García-Arellano S, Muñoz-Valle J, Rodríguez-Ruiz H, Fernández-Tilapa G. In Peripheral Blood Mononuclear Cells Helicobacter pylori Induces the Secretion of Soluble and Exosomal Cytokines Related to Carcinogenesis. IJMS. 2022;23(15):8801 [Crossref]
12- Portillo-Miño J, Bettin-Gonzalez D, Coral F. mRNA vaccines in gastric cancer: How close are we?. Vacunas (English Edition). 2024;25(1):88 [Crossref]
13- Nian X, Zhang J, Deng T, Liu J, Gong Z, Lv C, Yao L, Li J, Huang S, Yang X. AddaVax Formulated with PolyI:C as a Potential Adjuvant of MDCK-based Influenza Vaccine Enhances Local, Cellular, and Antibody Protective Immune Response in Mice. AAPS PharmSciTech. 2021;22(8) [Crossref]
14- Qin D, Wang L, Ni Y, Shan Z, Yang L. Knowledge, Attitude, and Practice of the Gastroenterology Department Patients Towards Chronic Gastritis in Shanxi Region: A Cross-Sectional Study. PPA. 2024;Volume 18:1769 [Crossref]
15- Zhang Z, Cui M, Ji X, Su G, Zhang Y, Du L. Candidate Antigens and the Development of Helicobacter pylori Vaccines. Helicobacter. 2024;29(4) [Crossref]